𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Radioimmunotherapy of experimental pancreatic cancer with 131I-labeled monoclonal antibody PAM4

✍ Scribed by David V. Gold; Thomas Cardillo; Yehuda Vardi; Rosalynn Blumenthal

Publisher
John Wiley and Sons
Year
1997
Tongue
French
Weight
184 KB
Volume
71
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

We examined the therapeutic efficacy of 131 I-labeled murine monoclonal antibody (MAb) PAM4 against human pancreatic cancers carried as xenografts in athymic nude mice. Animals bearing the CaPan1 tumor (0.2 cm 3 ) were either untreated or were given, 131 I-labeled nonspecific Ag8 antibody. By week 7 mean tumor size had grown 16.5 6 8.4-fold and 4.2 6 2.5-fold for the untreated and 131 I-Ag8-treated animals, respectively. In contrast, animals administered 131 I-PAM4 exhibited marked regression of tumors to an average of 15% of initial tumor volume. Since most pancreatic cancer patients present with large tumor burdens, the limitation of 131 I-PAM4 treatment with respect to initial tumor size was investigated in animals bearing tumors of approximately 0.5 cm 3 , 1.0 cm 3 and 2.0 cm 3 . Significant extension of survival time (G3-fold increase) was noted for both the 0.5 cm 3 and 1.0 cm 3 131 I-PAM4-treated groups, compared to their respective untreated controls. Even in the group bearing large 2.0-cm 3 tumors, survival was increased 2-fold over the control group. To further improve anti-tumor effects in large tumors, 2 injections of 131 I-PAM4 were administered at a 4-week interval to animals bearing tumors of approximately 1.0 cm 3 . Significant extended survival was noted for the group receiving 2 doses when compared to the group receiving only 1 dose. Int.

📜 SIMILAR VOLUMES

Combined 90Yttrium-DOTA-labeled PAM4 ant
Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft
✍ David V. Gold; David E. Modrak; Keith Schutsky; Thomas M. Cardillo 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 132 KB

## Abstract We have examined the application of ^90^Y‐DOTA‐cPAM4, anti‐MUC1 IgG, in combination with the front‐line drug gemcitabine as a potential therapeutic for pancreatic cancer. Athymic nude mice bearing CaPan1 human pancreatic cancer xenografts were administered 2 mg of gemcitabine on days 0,

Factors influencing hematologic toxicity
Factors influencing hematologic toxicity of radioimmunotherapy with 131I-labeled anti-carcinoembryonic antigen antibodies
✍ Malik E. Juweid; Cun-Hui Zhang; Rosalyn D. Blumenthal; Robert M. Sharkey; Robert 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB

## METHODS. Ninety-nine patients who received 131 I-labeled anti-CEA MoAb for the Garden State Cancer Center, Center for Molecutreatment of CEA-producing cancers were assessed for platelet and white blood lar Medicine and Immunology, Belleville, New cell toxicity based on the common Radiation Ther

Phase-I/II radio-immunotherapy study wit
Phase-I/II radio-immunotherapy study with iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab′)2 in patients with non-resectable liver metastases from colorectal cancer
✍ Marc Ychou; André Pelegrin; Patrick Faurous; Bruno Robert; Jean-Claude Saccavini 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 85 KB 👁 2 views

Experimental studies in nude mice with human coloncarcinoma grafts demonstrated the therapeutic efficiency of F(abЈ) 2 fragments to carcinoembryonic antigen (CEA) labeled with a high dose of 131 Iodine. A phase I/II study was designed to determine the maximum tolerated dose of 131 I-labeled F(abЈ) 2

Therapeutic efficacy and dose-limiting t
Therapeutic efficacy and dose-limiting toxicity of auger-electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: Evaluation of 125I- vs. 131I-labeled CO17-1A in a human colorectal cancer model
✍ Thomas M. Behr; George Sgouros; Vassilios Vougioukas; Stavros Memtsoudis; Stefan 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 187 KB

Recent clinical results suggest that higher anti-tumor efficacy may be achieved with internalizing monoclonal antibodies (MAbs) at lower toxicity when labeled with Augerelectron, as compared to conventional ␤-emitters. The aim of our study was to compare the toxicity and anti-tumor efficacy of the 1

Radiochemical synthesis and preliminary
Radiochemical synthesis and preliminary evaluation of anti-bladder cancer monoclonal antibody BDI-1 labeled with rhenium-188
✍ Rongfu Wang; Chungli Zhang; Lizhang Yu; Yifeng Guo; Ying Bai 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 103 KB

## Abstract The anti‐human bladder cancer monoclonal antibody BDI‐1 was radio‐labeled with rhenium‐188 by direct labeling methods using SnCl~2~ as reductant and MDP as stannous stabilizer or by indirect method using NHS‐ECM ester as bifunctional chelator. Radiochemical yields of 30±7.23% and 87.4±5